Bristol Myers Squibb's kidney cancer drug yielded disappointing trial results when used as a post-surgery combination treatment for patients with localized renal cell carcinoma.
A data review panel found that the combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) wasn’t much better than the placebo at preventing relapse or death in patients.
While the phase 3 CheckMate -914 trial did not meet its primary endpoints, the combo did have a safety profile that was consistent with previous studies of the drugs used on solid tumors.
Despite the recent flop, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval and has many indications approved for other cancers by itself, and in combination with Yervoy.
Part B of the CheckMate -91 trial tests Opdivo alone compared to placebo, and is still ongoing.
